► IMPORTANT NOTICE   to Health Care Workers Using the Protocol for High-Dose Intravenous Ascorbic Acid (Vitamin C) for the Treatment of Cancer in Patients Who Are Also Diabetic!

RATIONALE for INTRAVENOUS VITAMIN C in CANCER PATIENTS

Ron Hunninghake, M.D. Chief Medical Officer

INTRAVENOUS VITAMIN C and CANCER This article, written by Dr. Ron Hunninghake, was recently published in The Center's Health Hunter® Newsletter "There is actually a wide spectrum of medical uses for vitamin C. Evidence exists documenting it as the best antiviral agent now available ... IF used at the proper dose. Vitamin C can neutralize and eliminate a wide range of toxins. Vitamin C will enhance host resistance, greatly augmenting the immune system's ability to neutralize bacterial and fungal infections. Now the National Institutes of Health has published evidence demonstrating vitamin C's anti-cancer properties. With so many medical benefits, why do so few doctors know of them?" ► Read full article here...   More Vitamin C Research Papers: Orthomolecular Oncology Review: Ascorbic Acid and Cancer 25 years Later By Michael J. González, Jorge R. Miranda-Massari, Edna M. Mora, Angelik Guzmán, Neil H. Riordan, Hugh D. Riordan, Joseph J. Casciari, James A. Jackson, and Angel Romá-Franco, from Integrative Cancer Therapies 4(1); 2005 pp.32-44 Intravenous Ascorbic Acid: Protocol for its Application and Use By Hugh D. Riordan, Ronald E. Hunninghake, Neil H. Riordan, James A. Jackson, Xiao LongMeng, Paul Taylor, etal, from Puerto Rico Health Sciences Journal (2003) 22:3, 287-290 The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells By N. Mikirova, J.A. Jackson, J.P. Casciari and H.D. Riordan, from Journal of Orthomolecular Medicine (2001) 3, 177-182 Cytotoxicity of Ascorbate, Lipoic Acid, and Other Antioxidants In Hollow Fibre In Vitro Tumours By J.P. Casciari, N.H. Riordan, T.L. Schmidt, XL Meng, J.A. Jackson and H.D. Riordan, from British Journal of Cancer (2001) 84:11, 1544-1550 Clinical and Experimental Experiences with Intravenous Vitamin C By N.H. Riordan, H.D. Riordan, J.A. Jackson and J.P. Casciari, from Journal of Orthomolecular Medicine (2000) 15:4, 201-213 Different Fatty Acid Composition Between Normal and Malignant Cell Lines By X.L. Meng, N.H. Riordan, H.D. Riordan, J.A. Jackson, et al, from BioMedicina, (1999) 2:4, 5-7 Rethinking Vitamin C and Cancer: An Update on Nutritional Oncology By M.J. Gonzalez, E. Mora, N.H. Riordan, H.D. Riordan and P. Mojica, from Cancer Prevention International (1998) 3, 215-224 Intravenous Ascorbate as a Chemotherapeutic and Biologic Response Modifying Agent Bio-Communications Research Institute (1997) Intravenous Vitamin C in a Terminal Cancer Patient By N.H. Riordan, J.A. Jackson and H.D. Riordan, from Journal of Orthomolecular Medicine (1996) 11, 80-82 High-Dose Intravenous Vitamin C and Long-Time Survival of a Patient with Cancer of Head of the Pancreas By J.A. Jackson, H.D. Riordan, R.E. Hunninghake and N.H. Riordan, from Journal of Orthomolecular Medicine (1995) 10, 87-88 Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent By N.H. Riordan, H.D. Riordan, X. Meng, Y. Li and J.A. Jackson, from Medical Hypotheses (1995) 44, 207-213 Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney By H.D. Riordan, J.A. Jackson and Mavis Schultz, from Journal of Orthomolecular Medicine (1990) 5:1, 5-7